Rabin Medical Center
Petah Tikva, Israel
60 recruiting
Showing 1–20 of 92 trials
Recruiting
Phase 3
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
BeOne Medicines500 enrolled167 locationsNCT06973187
Recruiting
Phase 3
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Marginal Zone LymphomaRelapsed/Refractory Follicular Lymphoma
BeOne Medicines780 enrolled277 locationsNCT05100862
Recruiting
Phase 1Phase 2
Safety of HRX215 in Patients After Minor and Major Liver Resection
Liver ResectionColorectal Carcinoma Liver Metastases
HepaRegeniX GmbH80 enrolled6 locationsNCT06638502
Recruiting
Phase 3
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Multiple Myeloma
Pfizer492 enrolled273 locationsNCT06152575
Recruiting
Phase 3
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
Small Cell Lung CancerExtensive-stage Small-cell Lung Cancer
Amgen330 enrolled158 locationsNCT07005128
Recruiting
Phase 2Phase 3
Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
Gastroesophageal-junction CancerEsophageal AdenocarcinomaMetastatic Gastric Cancer+1 more
Pfizer840 enrolled71 locationsNCT07392892
Recruiting
Phase 3
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Prostate CancerCancer of the ProstateHormone Sensitive Prostate Cancer+1 more
Pfizer1,000 enrolled332 locationsNCT07028853
Recruiting
Phase 1
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
MelanomaNon-small Cell Lung CancerThyroid Cancer+10 more
Pfizer124 enrolled82 locationsNCT05538130
Recruiting
Phase 2Phase 3
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
Metastatic Pancreatic Ductal AdenocarcinomaCachexia
Pfizer982 enrolled188 locationsNCT06989437
Recruiting
Phase 3
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Relapsed or Refractory Multiple Myeloma
Celgene810 enrolled266 locationsNCT05519085
Recruiting
Phase 3
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Multiple Myeloma
Pfizer1,116 enrolled111 locationsNCT05623020
Recruiting
Phase 2Phase 3
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Urothelial Cancer
Bristol-Myers Squibb470 enrolled163 locationsNCT07106762
Recruiting
Phase 2Phase 3
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
Atherosclerotic Cardiovascular Disease in Patients With ESKD
CSL Behring3,110 enrolled547 locationsNCT05485961
Recruiting
Phase 2
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Carcinoma, Non-Small Cell Lung
Janssen Research & Development, LLC520 enrolled110 locationsNCT05498428
Recruiting
Phase 2Phase 3
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Crohn Disease
Janssen Research & Development, LLC1,092 enrolled363 locationsNCT07196722
Recruiting
Phase 3
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Colorectal Neoplasms
Janssen Research & Development, LLC1,000 enrolled237 locationsNCT06662786
Recruiting
Phase 3
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Colorectal Neoplasms
Janssen Research & Development, LLC700 enrolled247 locationsNCT06750094
Recruiting
Phase 3
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Leukemia, Myeloid, Acute
Janssen Research & Development, LLC600 enrolled250 locationsNCT06852222
Recruiting
Phase 3
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
Non-Muscle Invasive Bladder Neoplasms
Janssen Research & Development, LLC220 enrolled109 locationsNCT06919965
Recruiting
Phase 1Phase 2
Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
Non-Muscle Invasive Bladder Neoplasms
Janssen Research & Development, LLC235 enrolled59 locationsNCT05316155